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A newly identified parvovirus, human bocavirus
(HBoV), was found in 21 (8.3%) of 252 nasopharyngeal
aspirates from hospitalized children with lower respiratory
tract infection in Hunan Province, People’s Republic of
China. Viral loads were 104 to 1010 copies/mL. Phylo-
genetic analysis of the VP1 gene showed a single genetic
lineage of HBoV worldwide.
A
cute respiratory tract infections (ARTIs) are a leading
cause of hospitalization, illness, and death in infants
and young children (1–4). Respiratory syncytial virus
(RSV), human metapneumovirus (HMPV), influenza
viruses, human coronaviruses, rhinoviruses, and aden-
oviruses are some of the most important viral agents for
this group of patients. However, in a substantial proportion
of children with respiratory tract diseases, no pathogen can
be identified (1).
Until recently, the only parvovirus known to be path-
ogenic for humans is B19 (5). In 2005, a new human virus
of the genus Bocavirus considered to be pathogenic for
humans, provisionally named human bocavirus (HBoV),
was described in Sweden (1). Subsequently, HBoV infec-
tion was reported in children with ARTIs in Australia (6),
Japan (7), Canada (8), France (9), and the United States
(10). In our study, 252 nasopharyngeal aspirates (NPA)
obtained from November 3, 2005, to April 3, 2006, from
hospitalized children with lower respiratory tract infec-
tions were analyzed for the presence of HBoV because of
associated clinical manifestations.
The Study
Participants in the study were children <10 years of
age who were hospitalized from November 3, 2005, to
April 3, 2006, in Hunan Province, People’s Republic of
China. They were admitted mostly for bronchitis, pneumo-
nia, and bronchopneumonia; their NPA were collected for
investigation of the cause. All children were admitted 2–6
days after the onset of ARTI. All specimens were collected
after the parents of the enrolled children had given
informed consent.
DNAwas extracted from NPAspecimens by using the
QIAamp Viral DNA Mini Kit (QIAGEN, Beijing, China).
HBoV in extracted DNA was detected by PCR amplifica-
tion of a 291-bp fragment of the NS1 gene as described
previously (6). To acquire the complete sequence of the
VP1 gene, we used primers 5′-GATAACTGACGAG-
GAAATG-3′ and 5′-GAGACGGTAACACCACTA-3′
based on the published genomic sequence of HBoV
(GenBank accession no. NC_007455). The PCR cycle
included an initial heating at 95°C for 15 min; 40 cycles of
94°C for 45 s, 50°C for 45 s, and 72°C for 2 min; and a
final extension at 72°C for 10 min. Both short and long
PCR products were sequenced. Sequencing was performed
on an Applied Biosystems 3730 XL DNA Analyzer
(Applied Biosystems, Foster City, CA, USA) by using
both the forward and reverse primers. The complete
sequences of the VP1 gene obtained were aligned with
sequences available in GenBank by using Clustal X
(ftp://ftp-igbmc.u-strasbg.fr/pub/ClustalX/). A neighbor-
joining tree was constructed by the neighbor-joining
method using the MEGA 3.1 program (www.megasoft
ware.net) and sequences of canine minute virus (MVC)
and bovine parvovirus (BPV). Human parvovirus B19
(B19) was used as the outgroup.
A TaqMan real-time PCR targeting the NS1 region of
HBoV was conducted to quantify the viral load. In brief, 2
µL genomic DNA was amplified in a 25-µL PCR mixture
containing 5 µLABI TaqMan 2× PCR Master mix, 20 µM
of each primer, and 20 µM of the probe. The primer
sequences used were 5′-TAATGACTGCAGACAACGC-
CTAG-3′ and 5′-TGTCCCGCCCAAGATACACT-3′, and
the probe was 5′-FAM-TTCCACCCAATCCTGGT-MGB-
3′. The cycling conditions included initial incubations at
50°C for 2 min and 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s and 60°C for 30 s. Plasmid pGEM-T-NS1
containing the target sequences was constructed and used
as a positive control for copy number calculation.
Sensitivity of the PCR assay was 100 copies per reaction,
as determined by dilutions of the plasmid.
RNA was also extracted from each NPA specimen by
using the QIAamp Viral RNA Mini Kit (QIAGEN) to
screen for HMPV (11), RSV (12), influenza (A, B, and C)
(13), parainfluenza (types 1–4) (13), and human coron-
aviruses (229E, OC43, NL63, and HKU1) by standard
reverse transcription–PCR technique (13–15).
HBoV was detected by the diagnostic PCR in 21
(8.3%) of NPA specimens collected from 252 hospitalized
children with ARTI. Serum samples available from 2 of the
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positive patients (patient 7 and patient 10) had coinfection
with human coronavirus 229E. Among the HBoV-positive
patients, 17 (81%) were male, and 4 (19%) were female
(Table). The ages of the infected patients were 2 months to
3 years (median age 10.5 months), with the exception of a
10-year-old boy (patient 8). The most common clinical
signs and symptoms were cough (86%), fever (33%),
wheezing (33%), and diarrhea (29%) (Table). The 3 main
admission diagnoses were pneumonia (6 patients), bron-
chitis (6 patients), and bronchopneumonia (7 patients).
These patients had been admitted to hospital for 2 to 28
days. Chest radiographs were obtained from 12 patients;
all showed abnormal findings (6 had airspace shadows,
and 6 displayed coarse lung markings). Most HBoV-posi-
tive patients had no other underlying illness, with the
exception of 1 (patient 3) who had intracranial infection.
Although cough and diarrhea were more frequently found
in HBoV-infected children (86% and 29%, respectively)
than in HBoV-uninfected children (60% and 7.8%, respec-
tively), confirmation of the disease association of HBoV
infection requires the analysis of HBoV in a negative con-
trol group of healthy children.
HBoV viral loads in NPA specimens ranged from 2.4
× 104 to 2.5 × 1010 copies/mL(Table). The 2 positive serum
specimens (from patients 7 and 10) had 1.2 × 105 and 4.1
× 104 copies/mL, respectively, which were almost equal to
those found in their corresponding NPA specimens. Most
specimens had HBoV viral loads close to104 copies/mL.
However, 5 (24%) NPA specimens had viral loads >109
copies/mL.
The entire VP1 gene of HBoV was sequenced for 5
specimens that had adequate amounts of genomic DNA.
An alignment of VP1 sequences obtained from children in
China with those previously reported for the prototype
strains (ST1 and ST2 strains, GenBank accession
nos.DQ000495–DQ000496) showed only minor sequence
differences, with a nucleotide identity of 97.7% and an
amino acid identity of 98.1%. Thus, HBoV is a highly con-
served virus. Phylogenetic analysis of these sequences and
those from BPV, MVC, and B19 indicated that HBoV was
more related to BPV and MVC (Figure).
Conclusions
The prevalence of HBoV in children and the associat-
ed illness have not been well characterized. In this study,
we found that HBoV was prevalent in infants and young
children in China. The 8.3% prevalence rate is higher than
rates (3.1%–5.7%) previously reported for children in
Sweden, Australia, Japan, Canada, France, and the United
States (1,6–10). This difference could be due to the fact
that we screened specimens collected during the peak
ARTI season. Because this is the first finding of HBoV in
children in developing countries, whether the difference
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oping countries is unclear.
The symptoms associated with HBoV infection in
Chinese children are similar to those reported for children
from other countries (6–10) and are comparable to those
observed in children infected with other respiratory virus-
es, with a predominance of bronchitis or pneumonia
(11,13,15). Our results indicate several risk factors for
HBoV infection. Consistent with cases reported in the
United States (10), 57% of our HBoV-positive patients
were <12 months of age. Chest radiographs obtained from
all 12 patients had abnormal findings. Major diagnoses
were pneumonia, bronchitis, and bronchopneumonia.
Collectively, these findings support the notion that HBoV
infection may be associated with lower respiratory dis-
eases, as suggested by Allander et al. (1). We did not find
any association between the viral loads and disease sever-
ity and could not explain the difference in viral loads
among specimens. Nevertheless, the viral loads in serum
specimens were similar to those from NPA specimens in
the 2 HBoV-positive patients who had both serum and
NPA specimens. In our study, 29% of patients had diar-
rhea, which was also reported in 16% of HBoV–positive
patients in the United States (10). Unfortunately, we did
not collect stool specimens from HBoV-positive patients
for viral detection.
Detection of HBoV in serum specimens from 2
patients suggests that HBoV may cause viremia, which
was supported by the occurrence of intracranial infection
in 1 patient. However, further studies are required to con-
firm whether HBoV indeed causes viremia. In addition,
coinfection with human coronavirus 229E was identified
in 2 of the 21 HBoV-positive children in our study.
Although RSV, HMPV, and human coronavirus 229E were
detected in 13.5%, 7.9%, and 6.0%, respectively, of the
patients, no other children were found to be coinfected
with HBoV and another virus. This rate of coinfection is
lower than that reported for other countries (1,6,7,10).
Whether seasonal or other factors might account for this
difference remains to be determined.
In agreement with previous findings in other countries
(1,6,7,10), results of our study indicate that HBoVis a con-
served virus. Additional epidemiologic studies in different
regions and sequence analysis of other genes are required
to investigate the overall distribution, seasonality, and
genetic variations of HBoV and to examine the origin of
current HBoV endemics.
Acknowledgments
We thank Bing Zhang, Li-Li Zhong, Jin-Yan Zhou, Jing-
Song Liu, and Qiao-Tu Liu for their assistance in this study and
Dong-Yan Jin for critical reading of our manuscript.
Xiao-Wang Qu is a PhD student at the Institute for Viral
Disease Control and Prevention, Chinese Center for Disease
Control and Prevention. His research interests are in the epidemi-
ology and molecular biology of respiratory viruses.
References
1.  Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell
A, Andersson B. Cloning of a human parvovirus by molecular
screening of respiratory tract samples. Proc Natl Acad Sci U S A.
2005;102:12891–6. 
2.  Iwane MK, Edwards KM, Szilagyi PG, Walker FJ, Griffin MR,
Weinberg GA, et al. Population-based surveillance for hospitaliza-
tions associated with respiratory syncytial virus, influenza virus,
and parainfluenza viruses among young children. Pediatrics.
2004;113:1758–64. 
Human Bocavirus Infection, People's Republic of China
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 1, January 2007 167
Figure. Phylogenetic analysis of the complete VP1 nucleotide (A)
and amino acid (B) sequences of human bocavirus (HBoV).
Phylogenetic trees were constructed by the neighbor-joining
method by using MEGA 3.1 (www.megasoftware.net), and boot-
strap values were determined by 1,000 replicates. Viral sequences
in boldface were generated from the present study, and other ref-
erence sequences were obtained from GenBank. Bootstrap values
are shown at each branching point. The sequences generated
from the present study were deposited in GenBank under acces-
sion nos. DQ457413, DQ457415, DQ494201, DQ494203, and
DQ677522.3.  Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen
M, et al. Etiology of community-acquired pneumonia in 254 hospi-
talized children. Pediatr Infect Dis J. 2000;19:293–8. 
4.  Jartti T, Lehtinen P, Vuorinen T, Osterback R, van den Hoogen B,
Osterhaus AD, et al. Respiratory picornaviruses and respiratory
syncytial virus as causative agents of acute expiratory wheezing in
children. Emerg Infect Dis. 2004;10:1095–101. 
5.  Young NS, Brown KE. Parvovirus B19. N Engl J Med.
2004;350:586–97. 
6.  Sloots TP, McErlean P, Speicher DJ, Arden K, Nissen MD, Mackay
IA. Evidence of human coronavirus HKU1 and human bocavirus in
Australian children. J Clin Virol. 2006;35:99–102. 
7.  Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, et al.
Detection of human bocavirus in Japanese children with lower res-
piratory tract infections. J Clin Microbiol. 2006;44:1132–4. 
8.  Bastien N, Brandt K, Dust K, Ward D, Li Y. Human bocavirus
infection, Canada. Emerg Infect Dis. 2006;12:848–50. 
9.  FouLongne V, Rodiere M, Segondy M. Human bocavirus in chil-
dren. Emerg Infect Dis. 2006;12:862–3. 
10.  Arnold JC, Singh KK, Spector SA, Sawyer MH. Human bocavirus:
prevalence and clinical spectrum at a children’s hospital. Clin Infect
Dis. 2006;43:283–8. 
11.  Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL,
Pingsterhaus JM, Edwards KM, et al. Human metapneumovirus and
lower respiratory tract disease in otherwise healthy infants and chil-
dren. N Engl J Med. 2004;350:443–50. 
12.  Sampalis JS. Morbidity and mortality after RSV-associated hospi-
talizations among premature Canadian infants. J Pediatr.
2003;143:S150–6. 
13.  Chiu SS, Chan KH, Chu KW, Kwan SW, Guan Y, Poon LL, et al.
Human coronavirus NL63 infection and other coronavirus infec-
tions in children hospitalized with acute respiratory disease in Hong
Kong, China. Clin Infect Dis. 2005;40:1721–9. 
14.  Bellau-Pujol S, Vabret A, Legrand L, Dina J, Gouarin S, Petitjean-
Lecherbonnier J, et al. Development of three multiplex RT-PCR
assays for the detection of 12 respiratory RNA viruses. J Virol
Methods. 2005;126:53–63. 
15.  Woo PC, Lau SK, Tsoi HW, Huang Y, Poon RW, Chu CM, et al.
Clinical and molecular epidemiological features of coronavirus
HKU1-associated community-acquired pneumonia. J Infect Dis.
2005;192:1898–907.
Address for correspondence: Zhao-Jun Duan, Institute for Viral Disease
Control and Prevention, 100 Ying-Xin St, Xuan Wu District, Beijing,
100052, People's Republic of China; email: zhaojund@126.com
DISPATCHES
168 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 13, No. 1, January 2007
www.cdc.gov/ncidod/EID/cover_images/covers.htm